six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
Published 11 months ago • 196 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
0:59
5-year follow-up results of cll14: obinutuzumab venetoclax vs obinutuzumab chlorambucil in cll
-
1:16
cll14: venetoclax-obinutuzumab improves pfs and mrd in untreated, reduced fitness cll
-
5:54
cll14: venetoclax plus obinutuzumab for cll
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:09:27
us big tech crashes, asml tsm results discussion, thai beverage share swap
-
4:18
treatment options for chronic lymphocytic leukemia (cll)
-
1:56
the future of fixed-duration therapy in cll
-
10:24
fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
-
1:50
insights into the majic study: acalabrutinib venetoclax vs venetoclax obinutuzumab in cll
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
4:30
cll14 trial: obinutuzumab venetoclax vs obinutuzumab chlorambucil
-
1:00
reveng: venetoclax and obinutuzumab in cll
-
12:46
fixed duration treatment strategies in cll
-
2:25
update from murano trial: venetoclax-rituximab leads to slower clonal growth rate in cll
-
1:03
updates from the cll14 and cll2-give trials on cll
-
3:07
cll14 trial analysis
-
2:27
update on fixed-duration cohort of captivate trial for cll/sll
-
1:09
current and emerging treatment strategies for cll & defining the optimal treatment duration
-
1:28
the future of cll treatment